Literature DB >> 17206525

Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

Micha Levi1, Delia A Dempsey, Neal L Benowitz, Lewis B Sheiner.   

Abstract

To develop and compare methods that predict individual nicotine (NIC) clearance, which reflects CYP2A6 activity, using random saliva cotinine (COT) and trans 3'-hydroxycotinine (3HC) measurements. COT and 3HC saliva concentrations in smokers were simulated utilizing a mechanistic population pharmacokinetic model of NIC metabolism that was adapted from the one described in a companion paper. Four methods to predict NIC clearance using the metabolites concentrations were compared. The precision bias, and the fraction of predictions that are made with an absolute error below 25% were the performance measures evaluated. Four prediction methods were compared: (M1) reference method, an intercept slope model of the metabolite concentration ratios ([3HC]/[COT]) (M2) an intercept slope model of the natural logarithm of the metabolite ratios (M3) a spline of the logarithm of the metabolite ratios (M4) Maximal Posteriori Bayesian estimate of NIC clearance conditioned on the model, COT and 3HC concentrations. In addition, the effect of smoking patterns on the concentrations of COT and 3HC was evaluated. The precision, accuracy, and the fraction of predictions with an absolute error below 25%, were higher for methods M2-M4 compared to method M1. However, the differences between M2 and M4 were small. Additionally, smoking pattern did not affect the metabolite concentration profiles. Predicting NIC clearance using an intercept slope model of the natural logarithm of the ratio of 3HC to COT appears to be a relatively simple method that is better than using the metabolite ratio directly. This method has a bias of approximately -10%, precision of approximately 60%. The fraction of estimates below an absolute error of 25% is 43%. These results support use of M2 to estimate CYP2A6 activity in smokers in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206525     DOI: 10.1007/s10928-006-9026-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

Authors:  Y Rao; E Hoffmann; M Zia; L Bodin; M Zeman; E M Sellers; R F Tyndale
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

2.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

3.  Population pharmacokinetics of nicotine and its metabolites I. Model development.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

Review 4.  Cotinine as a biomarker of environmental tobacco smoke exposure.

Authors:  N L Benowitz
Journal:  Epidemiol Rev       Date:  1996       Impact factor: 6.222

Review 5.  CYP2A6 genetic variation and potential consequences.

Authors:  Chun Xu; Shari Goodz; Edward M Sellers; Rachel F Tyndale
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

6.  Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.

Authors:  Gary E Swan; Neal L Benowitz; Christina N Lessov; Peyton Jacob; Rachel F Tyndale; Kirk Wilhelmsen
Journal:  Pharmacogenet Genomics       Date:  2005-02       Impact factor: 2.089

7.  Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.

Authors:  R F Tyndale; E M Sellers
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

Review 8.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

9.  Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine.

Authors:  N L Benowitz; P Jacob; I Fong; S Gupta
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

10.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

View more
  30 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 2.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

3.  Population pharmacokinetics of nicotine and its metabolites I. Model development.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

Review 4.  Light and intermittent cigarette smokers: a review (1989-2009).

Authors:  Chris R E Coggins; E Lenn Murrelle; Richard A Carchman; Christian Heidbreder
Journal:  Psychopharmacology (Berl)       Date:  2009-10-03       Impact factor: 4.530

5.  Race, gender, and nicotine metabolism in adolescent smokers.

Authors:  Mark L Rubinstein; Saul Shiffman; Michelle A Rait; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-12-13       Impact factor: 4.244

6.  Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers.

Authors:  Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan
Journal:  Nicotine Tob Res       Date:  2015-05-19       Impact factor: 4.244

7.  Oral fluid nicotine markers to assess smoking status and recency of use.

Authors:  Karl B Scheidweiler; Gina F Marrone; Diaa M Shakleya; Edward G Singleton; Stephen J Heishman; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

Review 8.  Biomarkers to optimize the treatment of nicotine dependence.

Authors:  Robert A Schnoll; Frank T Leone
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

9.  Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM).

Authors:  Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Caryn Lerman; Neal Benowitz; Michael C Fiore; Timothy B Baker
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244

10.  Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study.

Authors:  Terril L Verplaetse; MacKenzie R Peltier; Walter Roberts; Kelly E Moore; Brian P Pittman; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2020-07-16       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.